Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Inductive Bio

Explore full profile

Inductive Bio is a company that provides a comprehensive solution for addressing ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) challenges in drug discovery and development

New York City, United StatesFounded 2021Biotech & Life Sciences
Valuation $100–250M Last recorded · 2025
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Inductive Bio and the history behind them.

About Inductive Bio

Inductive Bio is a cutting-edge startup that leverages advanced Machine Learning (ML) to optimize small molecule drug development. The company operates in the biotechnology and pharmaceutical sectors, serving clients such as pharmaceutical companies, biotech firms, and research institutions. Inductive Bio specializes in solving complex issues related to small molecule drugs, which are compounds used in medications to treat various diseases.

The core of Inductive Bio's business model revolves around its proprietary data and ML-driven software. The company boasts an extensive and meticulously curated dataset that helps map the drivers of small molecule ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). This dataset, combined with their advanced ML models, allows Inductive Bio to provide real-time predictions and data-driven insights during the drug design process. Essentially, their software acts as an experienced collaborator, offering valuable input as compounds are being developed.

Inductive Bio's revenue model is likely based on subscription fees or licensing agreements for their software and data services. By offering a user-friendly platform that requires minimal training, they make sophisticated ML tools accessible to entire teams, thereby accelerating the drug development process. Additionally, the company may generate income through consulting services, leveraging their deep expertise in both ML and drug development.

The team at Inductive Bio is composed of experts with extensive experience in machine learning and drug development. For instance, Alex Rich, Ph.D., a Machine Learning Engineer at the company, has a robust background in building reliable ML systems and has previously worked on patient risk stratification and electronic health records research.

In summary, Inductive Bio is at the forefront of integrating machine learning with drug development, providing invaluable tools and insights to accelerate the creation of effective small molecule drugs.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2021
Headquarters
New York City, United States
Employees
38
Open positions
2
Dealroom signal
91.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Core AI, Biotech and Pharma, AI Drug Discovery, Hard Tech, AI Applications, DT and LS, science-based
Technology
Artificial Intelligence, Machine Learning
Business model
Manufacturing
Client focus
b2b

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Dec 2025 $0 — Advanced Research Projects Agency for Health - ARPA-H ↗
SERIES A✓Equity / VC May 2025 $25M $100M Amino Collective · Andreessen Horowitz · CharacterVC · Lux Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Inductive Bio website traffic

Latest recorded traffic for Inductive Bio is 9.1K monthly website visits, up 30% over the last three months. Inductive Bio's team grew 65.2% over the past year.

Latest monthly visits9.1K 3-month web change+30% 1-year team growth+65.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

Series A3 investors entered at this stage

Other known investors2 additional known investors

  • Axial VC
  • Cailen DSa
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States97.4%
🇨🇦 Canada2.6%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Inductive Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inductive Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.